Sorrento Therapeutics Inc (SRNEQ) Gross Profit Margin starting from the second quarter 2023 to second quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Sorrento Therapeutics Inc   (SRNEQ)


Sorrento Therapeutics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SRNEQ Gross Profit Margin (Jun 30 2023)
Q2 		(Mar 31 2023)
Q1 		(Dec 31 2022)
Q4 		(Sep 30 2022)
Q3 		(Jun 30 2022)
Q2
Y / Y Revenue Change 31.1 %
Seq. Revenue Change -7.54 %
Revenue In Millions $15.03
Gross Profit Margin 56.31 %
Gross Profit Margin Total Ranking # 1638
Gross Profit In Millions $8.46
Y / Y Gross Profit Change 4.87 %
Seq. Gross Profit Change -31.6 %


Commenting Second Quarter 2023 Gross Profit Margin
Sorrento Therapeutics Inc experienced contraction in Gross Profit by -31.6 % to $15 millions and Revenue by -7.54 %, while Gross Profit Margin fell to 56.31 %, below company*s average Gross Profit Margin.


Observing second quarter 2023 results within Biotechnology & Pharmaceuticals industry 27 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 852 to 1638.
Learn about Gross Margin
SRNEQ's Gross Profit Margin second quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 28
Healthcare Sector # 295
Overall # 1615

Gross Profit Margin Statistics
High Average Low
99.11 % 71.12 % 34.19 %
(Sep 30 2017)   (Jun 30 2014)


SRNEQ Gross Income Trends • More of SRNEQ's Profitabilty Ratios • SRNEQ Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
SRNEQ's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
SRNEQ's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for SRNEQ's Competitors
Gross Profit Margin Profit Margin for Sorrento Therapeutics Inc 's Suppliers
Gross Profit Margin Profit Margin for SRNEQ's Customers

You may also want to know
SRNEQ's Annual Growth Rates SRNEQ's Profitability Ratios SRNEQ's Asset Turnover Ratio SRNEQ's Dividend Growth
SRNEQ's Roe SRNEQ's Valuation Ratios SRNEQ's Financial Strength Ratios SRNEQ's Gross Profit Growth
SRNEQ's Roa SRNEQ's Inventory Turnover Ratio SRNEQ's Growth Rates SRNEQ's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2023, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginJun 30 2023 MRQ Gross ProfitJun 30 2023 MRQ Revenue
Vir Biotechnology Inc   99.42 %$ 3.775  Millions$ 3.797  Millions
Agenus Inc  99.00 %$ 25.042  Millions$ 25.296  Millions
Biocryst Pharmaceuticals Inc   98.92 %$ 81.597  Millions$ 82.491  Millions
Ginkgo Bioworks Holdings Inc   97.48 %$ 78.534  Millions$ 80.568  Millions
Neurocrine Biosciences Inc   97.46 %$ 441.200  Millions$ 452.700  Millions
Exelixis Inc   96.23 %$ 452.143  Millions$ 469.848  Millions
Lineage Cell Therapeutics Inc   96.06 %$ 3.098  Millions$ 3.225  Millions
Fennec Pharmaceuticals Inc   95.55 %$ 3.177  Millions$ 3.325  Millions
Pluri Inc   91.89 %$ 0.102  Millions$ 0.111  Millions
Acorda Therapeutics Inc   89.67 %$ 26.610  Millions$ 29.675  Millions
Novavax inc   86.86 %$ 368.649  Millions$ 424.426  Millions
Zeo Scientifix Inc   86.70 %$ 1.058  Millions$ 1.221  Millions
Cyclo Therapeutics Inc   82.99 %$ 0.097  Millions$ 0.117  Millions
Zivo Bioscience Inc   82.69 %$ 0.003  Millions$ 0.004  Millions
Protalix Biotherapeutics inc   82.47 %$ 28.927  Millions$ 35.075  Millions
Gilead Sciences Inc   78.15 %$ 5,157.000  Millions$ 6,599.000  Millions
Halozyme Therapeutics Inc   77.35 %$ 170.968  Millions$ 221.038  Millions
Biogen Inc   75.87 %$ 1,863.300  Millions$ 2,456.000  Millions
Amgen Inc   74.05 %$ 5,173.000  Millions$ 6,986.000  Millions
Orchard Therapeutics Plc  70.07 %$ 5.125  Millions$ 7.314  Millions
Seagen Inc   70.07 %$ 423.079  Millions$ 603.832  Millions
Bio techne Corp  67.90 %$ 204.698  Millions$ 301.477  Millions
Scilex Holding Company  66.80 %$ 8.405  Millions$ 12.582  Millions
Vericel Corporation  65.20 %$ 29.941  Millions$ 45.922  Millions
Xtant Medical Holdings Inc   64.03 %$ 12.459  Millions$ 19.459  Millions
Adaptive Biotechnologies Corporation  63.39 %$ 31.016  Millions$ 48.926  Millions
Coherus Oncology inc   57.68 %$ 33.868  Millions$ 58.716  Millions
Sorrento Therapeutics Inc   56.31 %$ 8.461  Millions$ 15.025  Millions
Regenxbio Inc   52.57 %$ 10.502  Millions$ 19.977  Millions
Repligen Corp  50.17 %$ 79.862  Millions$ 159.169  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.